Dexcom, Inc. · NASDAQ:DXCM
Dexcom — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
25 slides from Dexcom's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 9, 2023 CONFIDENTIAL – DO NOT DISTRIBUTE
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward” looking statements that are based on our management’s beliefs and assumptions and on information currently available to management. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking
Slide 3: Our Mission: Empowering people to take control of health
Our Mission: Empowering people to take control of health 3
Slide 4: 2022 Performance
2022 Performance Strong Revenue Growth Enhanced Scale Preliminary 2022 revenue expected to be approximately $2.91 Over 500 basis points of operating expense leverage billion, representing organic growth of greater than 19%1 Grew the active Dexcom base by ~35% during 2022. Now serving nearly 1.7 mill
Slide 5: 2023 Outlook
2023 Outlook Objectives & FY23 Guidance Considerations Revenue of $3.35 – 3.49 billion • Global rollout of G7 (~15 – 20% Growth) • Temporary bridge program for G7 to enable early access • Gross margin progression as G7 scales Gross Margin of 62 - 63% • Expansion of Dexcom ONE into new geographies •
Slide 6: A Global Crisis that Remains Uncontrolled
A Global Crisis that Remains Uncontrolled Diabetes Diagnosis and Cost Global Diabetes Related Adults (aged 20-79) with Diabetes Globally Health Expenditures 783m in 2045E USD USD 537m in 2021 760b 966b 463m 2019 2021 in 2019 +27% increase 151m in 2000 Past 2 Years Source: IDF Atlas, 10th edition (20
Slide 7: Intermittent glucose monitoring is not enough for intensive insulin management
Glucose (mg/dl) 340 SMBG* 320 300 280 260 Intermittent 240 220 glucose monitoring 200 180 is not enough for 160 140 intensive insulin 120 100 Target Glucose Range management… 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hours) *As compared to Self Monitoring of Blood Glucose (SMBG) 7
Slide 8: Intermittent glucose monitoring is not enough for intensive insulin management
Glucose (mg/dl) 340 320 300 OVER 4 HOURS ABOVE 280 210 BEFORE SMBG* 260 Intermittent 240 220 ABOVE 140 FOR glucose monitoring 200 180 13.5 HOURS is not enough for 160 140 intensive insulin 120 100 Target Glucose Range management… 80 60 DANGEROUS LOW 40 FOR 1 HOUR 20 0 0 2 4 6 8 10 12 14 16 18 20 22
Slide 9: …and non-intensive type 2 diabetes management
Glucose (mg/dl) 340 SMBG* 320 300 280 260 240 220 …and non-intensive 200 180 type 2 diabetes 160 140 management 120 100 Target Glucose Range 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hours) *As compared to Self Monitoring of Blood Glucose (SMBG). 9
Slide 10: …and non-intensive type 2 diabetes management
Glucose (mg/dl) 340 320 300 280 260 APPROXIMATELY 17 HOURS ABOVE TARGET RANGE, INCLUDING 240 ~6 HOURS IN SEVERE HYPERGLYCEMIA (>250 mg/dl) 220 …and non-intensive 200 180 AVG GLUCOSE: 185 mg/dl type 2 diabetes 160 140 management 120 100 Target Glucose Range 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 2
Slide 11: We can do more
We can do more pexcom u
Slide 12: G7: The New Standard in CGM Technology
G7: The New Standard in CGM Technology Real-Time CGM Fully Disposable Factory Calibrated iCGM Simple Application Designed for Extended Significant Manufacturing Wear & Direct-to-Watch Cost Reduction Personalized Insights 30-Minute Warmup Most Accurate CGM 1 Only iCGM Trusted for Use in Pregnancy 1.
Slide 13: G7 Is Living up to its High Expectations
G7 Is Living up to its High Expectations DIRECT FEEDBACK For me, it is definitely a big I basically forgot it was there… step forward in terms of that is the dream, really. comfort and convenience. We are obsessed with how Once it was on and in, I didn’t quickly the sensors warm up, know it was ther
Slide 14: What's Next for G7?
What’s Next for G7? International Building Expanding Connected Markets Access Solutions Extending launch to additional Establishing reimbursement for G7 in US Leveraging world’s most connected CGM geographies: across our channels ecosystem1 to bring more choice to users • We are fully launched in 6
Slide 15: Core US Market
Insulin Using Population All Insulin ~7m IIT Core US Market ~4m Momentum and opportunity remain significant With coverage for basal insulin users there will be more people Estimated US IIT CGM Users – All companies* Estimated Reimbursed Population* with access to CGM than ever before T1 Commercial +
Slide 16: Commercial Access Efforts Empower our Customers
Commercial Access Efforts Empower our Customers Meeting our customers where they want to be met in either the pharmacy or durable medical equipment channels Simple to Prescribe Broad Customer Access Efficient Service Model Dexcom is the number one covered and most reimbursed CGM on the market1 1. Ma
Slide 17: Commercial Execution
Commercial Execution Growing presence within primary care STRATEGIC INITIATIVES Drove reimbursement through 01 clinical evidence (MOBILE study) Over the past two years: 02 Doubled size of sales force in 2021 We doubled total primary care prescriber Introduced sampling program base 03 to highlight th
Slide 18: Gaining Market Share Internationally
Gaining Market Share Internationally Entering new geographies Reducing administrative barriers Gaining reimbursement Well-positioned to extend growth Leveraging e-commerce platform momentum OUS Going direct in strategic markets 18
Slide 19: Dexcom's Portfolio Strategy: Meeting the Needs of Each Market
Dexcom’s Portfolio Strategy: Meeting the Needs of Each Market Broad Limited Tiered Reimbursement Markets Reimbursement Reimbursement G-Series G-Series Dexcom ONE Dexcom ONE • Leading Accuracy • Connected & Higher- • Simple & Accurate • E-Commerce & Connectivity Risk Populations Accessibility 19
Slide 20: OUS Markets
Access for 3.5 million additional people with diabetes over the past 18 months OUS Markets Significantly improving access UK Spain Germany Canada Australia Japan Other Countries We have successfully expanded coverage for G-Series and Dexcom ONE *Estimated Reimbursed Population based on Dexcom market
Slide 21: 3 Elements of an Effective Solution
User Engagement Health Outcomes Type 2 Diabetes 3 Elements of an Return on Investment Effective Solution 21
Slide 22: Type 2 Diabetes: 3 Elements of an Effective Solution
Type 2 Diabetes: 3 Elements of an Effective Solution User Engagement Health Outcomes Return on Investment Sustained engagement demonstrated Evidence generation through clinical Strong economic return to payers in non-intensive studies trials, real-world evidence, and pilots with key partners Example
Slide 23: Connectivity as a Competitive Advantage
Connectivity as a Competitive Advantage Differentiating through hardware and software Customers Automated Insulin Delivery Connected Pen Digital Health Apps Loved Ones Follow App Healthcare Providers Clarity Clinic 23
Slide 24: Empowering people to take control of health
Our Mission: Empowering people to take control of health Where We Are Where We Are Going • Type 1 • Type 2 Non-Insulin • Type 2 IIT • Pre-Diabetes • Type 2 Basal-Only • Gestational Diabetes • Patient Monitoring • Health & Wellness 24
Slide 25: This is our WHY
This is our WHY 25
Dexcom — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix